Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 8, 2012, Pages 1336-1342

  Shimizu, Taro ^a   Ichihara, Masako ^a   Yoshioka, Yasuo ^b   Ishida, Tatsuhiro ^a   Nakagawa, Shinsaku ^b   Kiwadaa, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Adenovirus; Anti polyethylene glycol immunoglobulin M; Liposome; PEGylation

Indexed keywords

ADENOVIRUS VECTOR; BOVINE SERUM ALBUMIN; CHOLESTEROL; COMPLEMENT; IMMUNOGLOBULIN M; LIPOSOME; MACROGOL; MACROGOL 2000; MACROGOL 3000; NANOPARTICLE; NEUTRALIZING ANTIBODY; OVALBUMIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE;

ADENOVIRUS; ANIMAL EXPERIMENT; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; COVALENT BOND; CROSS REACTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; NONHUMAN; RAT; SPLENECTOMY;

ADENOVIRIDAE; ANIMALS; CATTLE; IMMUNOGLOBULIN M; INJECTIONS, INTRAVENOUS; LIPOSOMES; MALE; OVALBUMIN; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SERUM ALBUMIN; SPLENECTOMY;

EID: 84864942367     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00276     Document Type: Article

References (40)

1. Werle M, Bernkop-Schnürch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids, 30, 351-367 (2006).
2. Constantinou A, Chen C, Deonarain MP. Modulating the pharmacokinetics of therapeutic antibodies. Biotechnol. Lett., 32, 609-622 (2010).
3. Xu L, Anchordoquy T. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J. Pharm. Sci., 100, 38-52 (2011).
4. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev., 54, 459-476 (2002).
5. Zalipsky S. Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bioconjug. Chem., 6, 150-165 (1995).
6. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov., 2, 214-221 (2003).
7. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev., 55, 1261-1277 (2003).
8. Sun X, Yang Z, Li S, Tan Y, Zhang N, Wang X, Yagi S, Yoshioka T, Takimoto A, Mitsushima K, Suginaka A, Frenkel EP, Hoffman RM. In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5′-phosphate supplementation. Cancer Res., 63, 8377-8383 (2003).
9. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today, 10, 1451-1458 (2005).
10. Wonganan P, Croyle MA. PEGylated adenoviruses: From mice to monkeys. Viruses, 2, 468-502 (2010).
11. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U.S.A., 88, 11460-11464 (1991).
12. Maeda H, Matsumura Y. EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy. Adv. Drug Deliv. Rev., 63, 129-130 (2011).
13. Krown SE, Northfelt DW, Osoba D, Stewart JS. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin. Oncol., 31 (Suppl. 13), 36-52 (2004).
14. Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, Batter V, Ngalula-Kabanga E, Dittrich C, Piccart M. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur. J. Cancer, 42, 882-887 (2006).
15. Gao JQ, Eto Y, Yoshioka Y, Sekiguchi F, Kurachi S, Morishige T, Yao X, Watanabe H, Asavatanabodee R, Sakurai F, Mizuguchi H, Okada Y, Mukai Y, Tsutsumi Y, Mayumi T, Okada N, Nakagawa S. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J. Control. Release, 122, 102-110 (2007).
16. Yao X, Yoshioka Y, Morishige T, Eto Y, Watanabe H, Okada Y, Mizuguchi H, Mukai Y, Okada N, Nakagawa S. Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis. Gene Ther., 16, 1395-1404 (2009).
17. Eto Y, Yoshioka Y, Ishida T, Yao X, Morishige T, Narimatsu S, Mizuguchi H, Mukai Y, Okada N, Kiwada H, Nakagawa S. Optimized PEGylated adenovirus vector reduces the anti-vector humoral immune response against adenovirus and induces a therapeutic effect against metastatic lung cancer. Biol. Pharm. Bull., 33, 1540-1544 (2010).
18. Yao X, Yoshioka Y, Morishige T, Eto Y, Narimatsu S, Kawai Y, Mizuguchi H, Gao JQ, Mukai Y, Okada N, Nakagawa S. Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy. Mol. Ther., 19, 1619-1625 (2011).
19. Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van Der Meer JW, Corstens FH, Boerman OC. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther., 292, 1071-1079 (2000).
20. Ishida T, Maeda R, Ichihara M, Irimura K, Kiwada H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J. Control. Release, 88, 35-42 (2003).
21. Ishida T, Ichihara M, Wang X, Kiwada H. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J. Control. Release, 115, 243-250 (2006).
22. Ishida T, Ichihara M, Wang X, Yamamoto K, Kimura J, Majima E, Kiwada H. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Release, 112, 15-25 (2006).
23. Bartlett GR. Colorimetric assay methods for free and phosphorylated glyceric acids. J. Biol. Chem., 234, 469-471 (1959).
24. Mizuguchi H, Kay MA. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum. Gene Ther., 10, 2013-2017 (1999).
25. Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum. Gene Ther., 9, 2577-2583 (1998).
26. Jevsevar S, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins. Biotechnol. J., 5, 113-128 (2010).
27. Richter AW, Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int. Arch. Allergy Appl. Immunol., 70, 124-131 (1983).
28. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res. Ther., 8, R12 (2006).
29. Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman HJ, Garratty G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer, 110, 103-111 (2007).
30. Rubin B. The immune response against hapten-autologous protein conjugates in the mouse. I. Specificity of antibodies produced during the primary response against dinitrophenylated mouse serum albumin. Eur. J. Immunol., 3, 26-32 (1973).
31. Klaus GG, Janossy G, Humphrey JH. The immunological properties of haptens coupled to thymus-independent carrier molecules. III. The role of the immunogenicity and mitogenicity of the carrier in the induction of primary IgM anti-hapten responses. Eur. J. Immunol., 5, 105-111 (1975).
32. Wang X, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J. Control. Release, 119, 236-244 (2007).
33. Ishihara T, Takeda M, Sakamoto H, Kimoto A, Kobayashi C, Takasaki N, Yuki K, Tanaka K, Takenaga M, Igarashi R, Maeda T, Yamakawa N, Okamoto Y, Otsuka M, Ishida T, Kiwada H, Mizushima Y, Mizushima T. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm. Res., 26, 2270-2279 (2009).
34. Kaminskas LM, McLeod VM, Porter CJ, Boyd BJ. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance. J. Pharm. Sci., 100, 5069-5077 (2011).
35. Cheng TL, Chen BM, Chern JW, Wu MF, Roffler SR. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjug. Chem., 11, 258-266 (2000).
36. Cheng TL, Wu PY, Wu MF, Chern JW, Roffler SR. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconjug. Chem., 10, 520-528 (1999).
37. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J. Control. Release, 122, 349-355 (2007).
38. Koide H, Asai T, Hatanaka K, Akai S, Ishii T, Kenjo E, Ishida T, Kiwada H, Tsukada H, Oku N. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int. J. Pharm., 392, 218-223 (2010).
39. Bondada S, Wu H, Robertson DA, Chelvarajan RL. Accessory cell defect in unresponsiveness of neonates and aged to polysaccharide vaccines. Vaccine, 19, 557-565 (2000).
40. Ishida T, Atobe K, Wang X, Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin- encapsulation and high-dose first injection. J. Control. Release, 115, 251-258 (2006).